Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serplulimab, Decitabine, and CAPOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
NCT07691632Phase 2Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Jun 2026
- Primary completion
- Dec 2027
- Countries
- 1
01
Overview
A Phase 2 trial of serplulimab, decitabine in colorectal cancer (CRC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
serplulimabdecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07691632.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07691632.